Lonza Group AG (LONN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lonza Group AG (LONN) has a cash flow conversion efficiency ratio of 0.085x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF783.00 Million) by net assets (CHF9.19 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Lonza Group AG - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Lonza Group AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Lonza Group AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lonza Group AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Prudential Financial Inc
NYSE:PRU
|
-0.014x |
|
Martin Marietta Materials Inc
NYSE:MLM
|
0.063x |
|
ASM INTL N.V. NY/1 EO-04
F:AVSN
|
0.041x |
|
CHINA PAC.IN.GR.GDR/5 YC1
F:75CB
|
N/A |
|
OTP Bank Nyrt
BUD:OTP
|
0.079x |
|
Beijing-Shanghai High Speed Railway Co Ltd
SHG:601816
|
0.027x |
|
Shaanxi Coal Industry Co Ltd
SHG:601225
|
0.097x |
|
Baidu Inc
NASDAQ:BIDU
|
0.009x |
Annual Cash Flow Conversion Efficiency for Lonza Group AG (2004–2025)
The table below shows the annual cash flow conversion efficiency of Lonza Group AG from 2004 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CHF9.19 Billion | CHF1.17 Billion | 0.127x | -6.23% |
| 2024-12-31 | CHF9.39 Billion | CHF1.27 Billion | 0.136x | -6.80% |
| 2023-12-31 | CHF9.51 Billion | CHF1.39 Billion | 0.146x | +52.24% |
| 2022-12-31 | CHF10.66 Billion | CHF1.02 Billion | 0.096x | -22.80% |
| 2021-12-31 | CHF9.82 Billion | CHF1.22 Billion | 0.124x | -24.52% |
| 2020-12-31 | CHF6.88 Billion | CHF1.13 Billion | 0.164x | +9.29% |
| 2019-12-31 | CHF6.57 Billion | CHF986.00 Million | 0.150x | -12.69% |
| 2018-12-31 | CHF6.29 Billion | CHF1.08 Billion | 0.172x | +26.43% |
| 2017-12-31 | CHF6.18 Billion | CHF841.00 Million | 0.136x | -57.39% |
| 2016-12-31 | CHF2.35 Billion | CHF752.00 Million | 0.319x | -8.00% |
| 2015-12-31 | CHF2.13 Billion | CHF741.00 Million | 0.347x | +53.06% |
| 2014-12-31 | CHF2.13 Billion | CHF483.00 Million | 0.227x | -7.65% |
| 2013-12-31 | CHF2.13 Billion | CHF522.00 Million | 0.246x | -16.80% |
| 2012-12-31 | CHF2.41 Billion | CHF710.00 Million | 0.295x | +214.59% |
| 2011-12-31 | CHF2.36 Billion | CHF221.00 Million | 0.094x | -55.40% |
| 2010-12-31 | CHF2.39 Billion | CHF502.00 Million | 0.210x | +19.06% |
| 2009-12-31 | CHF2.39 Billion | CHF422.00 Million | 0.177x | +80.58% |
| 2008-12-31 | CHF1.79 Billion | CHF175.00 Million | 0.098x | -72.54% |
| 2007-12-31 | CHF1.81 Billion | CHF644.00 Million | 0.356x | +34.68% |
| 2006-12-31 | CHF1.61 Billion | CHF425.00 Million | 0.264x | -4.59% |
| 2005-12-31 | CHF1.49 Billion | CHF413.00 Million | 0.277x | +100.10% |
| 2004-12-31 | CHF1.28 Billion | CHF178.00 Million | 0.139x | -- |
About Lonza Group AG
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biol… Read more